```json
{
"content": [
{
"type": "paragraph",
"content": "The Minimal Residual Disease (MRD) Testing market focuses on detecting residual cancer cells post-treatment, critical for improving patient outcomes and guiding therapeutic decisions. With the MRD Testing market size projected to reach $2.5 billion by 2025, driven by advancements in molecular diagnostics and rising demand for personalized oncology, the growth outlook for the 2026–2033 period is robust. Industry expansion is further accelerated by the adoption of next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies, which enhance sensitivity and specificity. The market is poised for a compound annual growth rate (CAGR) of 13.5% during the forecast period, fueled by increasing incidence of hematological cancers and favorable reimbursement policies."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["PCR", "Flow Cytometry", "NGS"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.5], // PCR
[0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7], // Flow Cytometry
[0.3, 0.4, 0.5, 0.6, 0.7, 0.9, 1.1, 1.4, 1.7, 2.0, 2.3, 2.6, 3.0] // NGS
]
}
},
{
"type": "paragraph",
"content": "Key forces shaping the MRD Testing market forecast include technological shifts toward non-invasive liquid biopsy solutions and AI-driven data analytics, which are redefining diagnostic precision. Regulatory developments, such as FDA approvals for MRD assays in multiple cancer types, are also propelling market confidence. North America remains the largest region, driven by high healthcare expenditure and established oncology infrastructure, while Asia-Pacific is the fastest-growing region due to expanding access to advanced diagnostics and rising cancer awareness. Strategic collaborations among diagnostics firms and pharmaceutical companies will further accelerate innovation, ensuring the MRD Testing market remains a cornerstone of precision oncology."
}
]
}
```
